Pro-stride and extracorporeal shockwave therapy as treatment of lateral collateral desmopathy of the proximal interphalangeal joint in a Dutch Warmblood gelding.

A 6-year-old chestnut Dutch Warmblood gelding was presented for right front lameness 1 mo after being cast in a stall at a 1.20-meter jumping event. Lameness work-up revealed mild lameness on the right and left front legs, with diffuse swelling over the right front pastern. Ultrasonic evaluation yielded suspicion of collateral desmopathy of the proximal interphalangeal joint that was subsequently confirmed via MRI. Two weeks after initial evaluation, the proximal and distal interphalangeal joints were injected with Pro-Stride Autologous Protein Solution, immediately followed by Extracorporeal Shockwave Therapy of the lateral and medial collateral ligaments. Follow-up at 2 and 3 mo after treatment revealed reduced joint effusion of the proximal and distal interphalangeal joints, as well as improved fiber organization of the associated collateral ligaments. This should inform practitioners that multimodal therapeutic treatments including biologics and stimulation of healing through sound waves can aid in ligamentous injuries in sport horses.

Thérapie avec Pro-Stride et ondes de choc extracorporelles comme traitement de la desmopathie collatérale latérale de l'articulation interphalangienne proximale chez un hongre Warmblood hollandais. Un hongre Warmblood hollandais alezan de 6 ans a été présenté pour boiterie avant droite 1 mois après s'être blessé lors d'une compétition de sauts à 1,20 mètre. Le bilan de boiterie a révélé une légère boiterie sur les pattes avant droite et gauche, avec une enflure diffuse sur le paturon avant droit. L'examen échographique a révélé une suspicion de desmopathie collatérale de l'articulation interphalangienne proximale qui a ensuite été confirmée par imagerie par résonnance magnétique. Deux semaines après l'évaluation initiale, les articulations interphalangiennes proximales et distales ont reçu une injection de solution de protéines autologues Pro-Stride, immédiatement suivie d'une thérapie par ondes de choc extracorporelles des ligaments collatéraux latéral et médial. Le suivi à 2 et 3 mois après le traitement a révélé un épanchement articulaire réduit des articulations interphalangiennes proximales et distales, ainsi qu'une meilleure organisation des fibres des ligaments collatéraux associés.Ceci devrait informer les praticiens que les traitements thérapeutiques multimodaux, y compris les produits biologiques et la stimulation de la guérison par des ondes sonores, peuvent aider dans les blessures ligamentaires chez les chevaux de sport.(Traduit par Dr Serge Messier).

Shockwave Therapy in Veterinary Rehabilitation.

Extracorporeal shockwave therapy (ESWT) is a noninvasive treatment that involves the transcutaneous delivery of high-energy sound waves into tissue creating therapeutic effects. Shockwaves are nonlinear, high-pressure, high-velocity acoustic waves characterized by low tensile amplitude, short rise time to peak pressure, and a short duration (less than 10 milliseconds). ESWT has been shown to increase the expression of cytokines and growth factors leading to decreased inflammation, neovascularization, and cellular proliferation; activation of osteogenesis by osteoblast differentiation and then by increased proliferation; inhibition of cartilage degeneration and rebuilding of subchondral bone; and increased serotonin in the dorsal horn and descending inhibition of pain signals. Musculoskeletal conditions that can benefit from ESWT include osteoarthritis, tendinopathies, fracture/bone healing, and wound healing.

Equine shock wave therapy - where are we now?

Over the past three decades, electrohydraulic extracorporeal shock wave therapy (ESWT) as a treatment modality for equine orthopaedic disorders has sparked exponential interest among practitioners, but its clinical applications are quickly evolving and a current review highlighting modernised equine clinical use is lacking. The objective of this review is to summarise the most current ESWT technology, evidence for its use, proposed mechanisms of action and clinical applications in horses while also highlighting the areas requiring further investigation. The three ways to generate a shock wave are through electrohydraulic, electromagnetic or piezoelectric mechanisms, but over the last decade, electrohydraulic systems have predominated due to the ability to focus and control a therapeutic waveform. Shock waves' primary physical effect is believed to be via mechanotransduction leading to cellular activation and downstream signalling. Experimentally, ESWT's effects on osseous, connective tissue and wound healing via various mechanisms of action have been reported both in the human and veterinary literature. Clinical trials have investigated ESWT's orthopaedic application including osteoarthritis, thoracolumbar pain, navicular syndrome, tendinopathy and proximal suspensory desmopathy, with its concomitant use with biologics representing an area of active research. Direct ESWT protocol comparisons in terms of long-term efficacy with variables of energy, depth and exposed tissue types are still lacking with evidence-based recommendations being largely anecdotal. Technical advancements to facilitate the safe and judicious use of ESWT include human and equine hearing protection, light sedation and/or patient restraint. Efforts to ensure the safe and judicious use of ESWT and its analgesic effects are ongoing.

Extracorporeal Shockwave Therapy for Musculoskeletal Pathologies.

Extracorporeal shockwave therapy has multiple applications in veterinary musculoskeletal pathologies. Primary indications include tendinopathies, malunion fractures, patellar desmitis, and osteoarthritis. There are multiple types of shockwave generators. Current evidence in the canine literature is primarily on electrohydraulic and radial pressure wave generators. Treatment protocols from one machine are not equivalent to other machines, and data should not be extrapolated between studies.

The effect of extracorporeal shockwave on liposomal bupivacaine in a tibial plateau leveling osteotomy model.

OBJECTIVE: To determine the effect of extracorporeal shock wave (ESWT) on liposomal bupivacaine in a tibial-plateau-leveling osteotomy model. STUDY DESIGN: In vitro study. SAMPLE POPULATION: Ten samples per group. METHODS: In addition to a control group (sham treatment), five treatment groups were defined as A, energy (E) 3 (0.22 mJ/mm2 ), 360 pulses per minute (p/m); B, E6 (0.29 mJ/mm2 ), 360 p/m; C, E8 (0.39 mJ/mm2 ), 360 p/m; D, E6, 480 p/m; E, E8 480 p/m. Two-milliliter aliquots of liposomal bupivacaine were placed in a gelatin chamber and treated with 1000 pulses according to group. All samples remained in the chamber for 170 seconds to reflect the longest treatment group. Free bupivacaine concentrations were determined after treatment with high-performance liquid chromatography. RESULTS: The median free bupivacaine concentration was reported as control, 1.90 mg/mL; A, 2.10 mg/mL; B, 2.03 mg/mL; C, 2.94 mg/mL; D, 2.71 mg/mL; E, 4.35 mg/mL. Groups C (P = .027), D (P = .034), and E (P = .002) were different from the control group. Groups C (P = .0025) and D (P = .0025) were different from group E. Additional intertreatment group differences were found. CONCLUSION: Extracorporeal shock wave therapy caused a dose-dependent release of bupivacaine; however, there was no significant release of bupivacaine from liposomes when ESWT was applied at currently recommended therapeutic settings in this model. CLINICAL SIGNIFICANCE: This in vitro study provides evidence that concurrent electrohydraulic ESWT and liposomal bupivacaine is likely safe at currently recommended settings, however, higher energy and pulse frequency settings should be avoided.

Characterization of the use of shock wave therapy among equine veterinarians.

Extracorporeal shock wave therapy (ESWT) research has prioritized mechanism of action and efficacy. Data regarding frequency of use and clinical opinion are not available. A web-based survey was offered to members of the American Association of Equine Practitioners; 144 responses were obtained. Frequency of ESWT use by respondents was as follows: daily by 8.3% (12/144), at least once weekly by 36.8% (53/144), at least once per month by 22.9% (33/144), less than once per month by 19.4% (28/144), and never by 12.5% (18/144) of respondents. The most common reason for use was to treat ligamentous injuries. Opinion of efficacy was variable.

La recherche sur la thérapie extra-corporelle par ondes de choc (ESWT) a priorisé le mécanisme d'action et l'efficacité. Les données concernant la fréquence d'utilisation et l'opinion clinique ne sont pas disponibles. Un sondage sur le web fut offert aux membres de l'American Association of Equine Practitionners; 144 réponses furent obtenues. La fréquence d'utilisation d'ESWT par les répondants était la suivante : quotidiennement par 8,3 % (12/144), au moins une fois semaine par 36,8 % (53/144), au moins une fois par mois 22,9 % (33/144), moins d'une fois par mois par 19,4 % (28/144) et jamais par 12,5 % (18/144) des répondants. La raison la plus fréquente pour son utilisation était pour traiter des blessures aux ligaments. Les opinions sur son efficacité étaient variables.(Traduit par Dr Serge Messier).

Inflammatory mediators are potential biomarkers for extracorporeal shockwave therapy in horses.

BACKGROUND: Extracorporeal shockwave therapy (ESWT) can potentially mask painful injuries in equine athletes. Tests to detect whether a horse has received ESWT prior to competition are needed. Extracorporeal shockwave therapy is known to affect inflammatory mediators in other species, and if these mediators are altered in the horse, these could serve as biomarkers of ESWT. OBJECTIVES: To test the hypothesis that a single application of ESWT will alter the circulating protein concentrations of 10 inflammatory mediators in horse plasma. STUDY DESIGN: Prospective repeated measures experimental study. METHODS: Eleven healthy horses were administered a single dose of ESWT on the dorsal surface of proximal MCIII. Blood samples were collected at -168, -144, -120, -96, -72, -70, -68, -66, -48, -24, -6, -4, -2, 0 h before and 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after ESWT. Plasma concentrations of interleukin 1 beta (IL-1ß), IL-1 receptor antagonist (IL-1RA), IL-2, IL-4, IL-6, IL-10, IL-15, interferon gamma (IFN-γ), soluble toll-like receptor 2 (sTLR2) and tumour necrosis factor alpha (TNF-α) were measured to assess the effects of ESWT on these mediators. RESULTS: Baseline concentrations of inflammatory mediators did not change substantially during the week prior to ESWT. Plasma concentrations of five inflammatory factors changed following ESWT. IL-1ß and IL-6 were significantly down-regulated (P<0.01), while TNF-α, IL-1RA and TLR2 were significantly up-regulated (P<0.01). The remaining cytokines were not significantly affected by ESWT. MAIN LIMITATIONS: This study was performed in a small number of sedentary, healthy pasture-kept horses using a single dose of ESWT applied to a single location. Additional studies are necessary to determine the effect of ESWT on inflammatory mediators in athletic horses undergoing treatment for musculoskeletal injuries. CONCLUSIONS: Plasma concentrations of TNF-α, IL-1ß, IL-1RA, IL-6 and TLR2 were significantly affected by ESWT, and deserve further investigation as possible biomarkers of ESWT.

Extracorporeal shockwave therapy raises mechanical nociceptive threshold in horses with thoracolumbar pain.

BACKGROUND: Although extracorporeal shockwave therapy (ESWT) is a common treatment for horses with back pain, effects on mechanical nociceptive threshold (MNT) and multifidus muscle cross sectional area (CSA) in the spine are unknown. OBJECTIVES: To evaluate effects of ESWT on spinal MNT and multifidus muscle CSA in horses with thoracolumbar pain. STUDY DESIGN: Non-randomised trial. METHODS: Thoracolumbar spines of 12 horses with thoracolumbar pain were radiographed to document existing pathology. Each horse received three ESWT treatments, 2 weeks apart (days 0, 14, 28). Palpation scores were documented (days 0, 45 and 65). Ultrasonographic CSA of left and right multifidus muscles was recorded at T12, T14, T16, T18, L3 and L5 (days 0, 45 and 65). MNT was measured at the same spinal sites every 7 days (day 0-56). RESULTS: Mechanical nociceptive threshold in 10/12 horses (83%) was greater at each time point compared with day 0 (P < 0.05). Mechanical nociceptive threshold increased at all time points at six sites in 2/12 (16%), at five sites in 3/12 (25%), at four sites in 4/12 (33%) and at one site in 1/12 (8%; P < 0.05). Mechanical nociceptive threshold average per cent  increase from day 0 to 56 was 64% for the thoracic region (T12-T18) and 29% for the lumbar region (L3-L5). There was no statistical difference in MNT from day 35 to 56 (P = 0.25). A bimodal analgesic trend was observed following ESWT. Degree of radiographic change was not associated with response to treatment. No significant change in multifidus muscle CSA was observed. MAIN LIMITATIONS: Small study size and lack of control group. CONCLUSIONS: Three treatments of ESWT 2 weeks apart raised MNT over a 56-day period in horses with back pain, but did not influence change in CSA of the multifidus muscle. While ESWT appears justifiable for analgesia, physiotherapeutic techniques may be necessary in conjunction for concurrent muscle rehabilitation.

Extracorporeal shock wave therapy improves short-term limb use after canine tibial plateau leveling osteotomy.

OBJECTIVE: To determine the influence of postoperative extracorporeal shock wave therapy (ESWT) on hind limb use after tibial plateau leveling osteotomy (TPLO). STUDY DESIGN: Randomized, prospective clinical trial. ANIMALS: Sixteen client-owned dogs, 2 to 10 years old weighing 18 to 75 kg. METHODS: Dogs were randomly assigned to treatment cohorts, TPLO with ESWT (ESWT, n = 9) or TPLO without ESWT (control, n = 7). Treatment consisted of 1000 pulses at 0.15 mJ/mm2 immediately and 2 weeks after surgery. Subjective pain, stifle goniometry, stifle circumference, peak vertical force (PVF) and vertical impulse (VI) were measured before surgery, prior to ESWT, and 2 and 8 weeks after surgery. Measures were compared between treatments at each time point and among time points for each treatment (P < .05). RESULTS: The PVF (5.5 ± 1.0 N/kg, mean ± SD) and VI (0.67 ± 0.14 N-s/kg) of surgically treated limbs in the ESWT cohort were higher 8 weeks after surgery compared with preoperative (3.8 ± 1.1 N/kg, P < .0001 and 0.47 ± 0.21 N-s/kg, P = .0012, respectively) values. In the control cohort, PVF (2.9 ± 1.3 N/kg, P = .0001) and VI (0.33 ± 0.20 N-s/kg, P = .0003) 2 weeks after surgery and VI (0.42 ± 0.2 N-s/kg, P = .0012) 8 weeks after surgery were lower (4.59 ± 2.33 N/kg and 0.592 ± 0.35 N-s/kg, respectively) than before surgery. Other parameters did not differ between groups. CONCLUSION: Weight bearing increased faster after TPLO in dogs treated with postoperative ESWT. CLINICAL SIGNIFICANCE: This study provides evidence to consider adjunct ESWT after TPLO.

Prospective randomized comparison of platelet rich plasma to extracorporeal shockwave therapy for treatment of proximal suspensory pain in western performance horses.

Proximal suspensory desmitis (PSD) is a frequent cause of lameness in the performance horse. Extracorporeal shockwave therapy (EST) and platelet rich plasma (PRP) have become common treatments for PSD yet clinical data on efficacy is limited. The main objective of this randomized, prospective clinical study was to compare long-term effectiveness of EST and PRP in Western performance horses. One hundred horses with lameness localized to the proximal suspensory ligament received treatment with either PRP or EST following baseline ultrasonographic evaluation. A veterinarian and agent evaluated the horses for lameness independently four days following the first treatment and long-term follow up was obtained from the agent at six and twelve months. Four days post treatment, horses treated with EST had significantly greater lameness improvement compared to PRP. At one-year horses with less severe baseline ultrasound changes (grades 0-1) appeared to respond better (degree of lameness) with EST treatment whereas horses with more severe ultrasound changes (grade 2) responded better to PRP. Horses with baseline lameness graded 1 or 2 were 5.1 times more likely to be back in work at 1 year compared to those presenting with grade 3 or 4. EST treatment was associated with going back to work 3.8 times more at one year compared to PRP independent of baseline ultrasound score. Both PRP and EST can be expected to yield favorable therapeutic responses in Western performance horses with lameness localized to the proximal suspensory region. Baseline ultrasound may guide treatment selection.